A Phase Ⅱ, Multicenter, Randomized, Single-Blind, Placebo-Controlled, Evaluation of the Safety, Efficacy of HR021618 for Pain Management Following Orthopaedic Surgery
Latest Information Update: 06 Dec 2022
At a glance
- Drugs HR 021618 (Primary)
- Indications Postoperative pain
- Focus Therapeutic Use
- Sponsors Jiangsu Hengrui Medicine Co.
- 05 Aug 2021 Planned End Date changed from 31 May 2021 to 8 Aug 2021.
- 05 Aug 2021 Status changed from recruiting to active, no longer recruiting.
- 12 Jan 2021 New trial record